Genetics of HDL-C: A causal link to atherosclerosis? Topical collection on genetics

Current Atherosclerosis Reports

Volumn 15, Issue 6, 2013, Pages

  Van Capelleveen, Julian C ^a   Bochem, Andrea E ^a   Motazacker, M Mahdi ^a   Hovingh, G Kees ^a   Kastelein, John J P ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Apolipoprotein A I; Atherosclerosis; ATP binding cassette transporter A1; Cardiovascular disease; Cholesteryl ester transport protein; Endothelial lipase; Genetics; Genome wide association; HDL cholesterol; Lecithin cholesterol acyltransferase; Mendelian randomization; Phospholipid transfer protein; Scavenger receptor class B type 1

Indexed keywords

ABC TRANSPORTER A1; ABC TRANSPORTER G1; ANACETRAPIB; APOLIPOPROTEIN A1; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; DALCETRAPIB; ENDOTHELIAL LIPASE; EVACETRAPIB; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PHOSPHOLIPID TRANSFER PROTEIN; SCAVENGER RECEPTOR BI; TA 8995; TORCETRAPIB; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG;

ABCA1 GENE; APOA1 GENE; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; GENE MUTATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; LIPID METABOLISM; MENDELIAN RANDOMIZATION ANALYSIS; MOLECULAR GENETICS; MOLECULAR PATHOLOGY; NONHUMAN; PROTEIN ANALYSIS; PROTEIN FUNCTION; RISK BENEFIT ANALYSIS; RISK REDUCTION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; METABOLISM; RISK FACTOR;

ATHEROSCLEROSIS; CHOLESTEROL, HDL; GENETIC PREDISPOSITION TO DISEASE; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 84891414969     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-013-0326-8     Document Type: Article

References (93)

1. Lewington S, Whitlock G, Clarke R, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007;370(9602):1829-39. (Pubitemid 350180032)
2. Di Angelantonio E, Sarwar N, Perry P, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302(18):1993-2000.
3. Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007;357(13):1301-10. (Pubitemid 47481452)
4. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383-9.
5. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med. 1996;335(14):1001-9. (Pubitemid 26338729)
6. Fisher EA, Feig JE, Hewing B, et al. High-density lipoprotein function, dysfunction, and reverse cholesterol transport. Arterioscler Thromb Vasc Biol. 2012;32(12):2813-20. Excellent recent review on HDL functionality.
7. Navab M, Reddy ST, Van Lenten BJ, Fogelman AM. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol. 2011;8(4):222-32.
8. Soran H, Hama S, Yadav R, Durrington PN. HDL functionality. Curr Opin Lipidol. 2012;23(4):353-66.
9. Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255-67.
10. Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367(22):2089-99.
11. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357(21):2109-22. (Pubitemid 350146106)
12. ™ (Extended-Release Niacin / Laropiprant) Did Not Achieve Primary Endpoint. Press release. December 20, 2012.
13. Weiss LA, Pan L, Abney M, Ober C. The sex-specific genetic architecture of quantitative traits in humans. Nat Genet. 2006;38(2):218-22. (Pubitemid 43177237)
14. Teslovich TM, Musunuru K, Smith AV, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature. 2010;466(7307):707-13.
15. Asselbergs FW, Guo Y, Van Iperen EPA, et al. Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. Am J Hum Genet. 2012;91(5):823-838. One of the most recent large scale gene centric meta-analysis on lipid heritablity.
16. Calabresi L, Baldassarre D, Castelnuovo S, et al. Functional lecithin: cholesterol acyltransferase is not required for efficient atheroprotection in humans. Circulation. 2009;120(7):628-35.
17. Hovingh GK, Hutten BA, Holleboom AG, et al. Compromised LCAT function is associated with increased atherosclerosis. Circulation. 2005;112(6):879-84. (Pubitemid 41170075)
18. Van Dam MJ, De Groot E, Clee SM, et al. Association between increased arterial-wall thickness and impairment in ABCA1-driven cholesterol efflux: an observational study. Lancet. 2002;359(9300):37-42. (Pubitemid 34119194)
19. Bochem AE, Van Wijk DF, Holleboom AG, et al. ABCA1 mutation carriers with low high-density lipoprotein cholesterol are characterized by a larger atherosclerotic burden. Eur Heart J. 2012. doi: 10.1093/eurheartj/ehs376.
20. •• Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet. 2012;380(9841):572-80. Recent Mendelian randomization study that found no association between EL gene variation, HDL-C values and CVD risk.
21. Haase CL, Tybjærg-Hansen A, Qayyum AA, et al. LCAT, HDL cholesterol and ischemic cardiovascular disease: a mendelian randomization study of HDL cholesterol in 54,500 individuals. J Clin Endocrinol Metab. 2012;97(2):E248-56.
22. Joy T, Wang J, Hahn A, Hegele RA. APOA1 related amyloidosis: a case report and literature review. Clin Biochem. 2003;36(8):641-5. (Pubitemid 37434032)
23. Ramella NA, Rimoldi OJ, Prieto ED, et al. Human apolipoprotein A-I-derived amyloid: its association with atherosclerosis. PLoS One. 2011;6(7):e22532.
24. Hovingh GK, De Groot E, Van der Steeg W, et al. Inherited disorders of HDL metabolism and atherosclerosis. Curr Opin Lipidol. 2005;16(2):139-45. (Pubitemid 40515887)
25. Wada M, Iso T, Asztalos BF, et al. Marked high density lipoprotein deficiency due to apolipoprotein A-I Tomioka (codon 138 deletion). Atherosclerosis. 2009;207(1):157-61.
26. Al-Sarraf A, Al-Ghofaili K, Sullivan DR, et al. Complete Apo AI deficiency in an Iraqi Mandaean family: case studies and review of the literature. J Clin Lipidol. 2010;4(5):420-6.
27. Santos RD, Schaefer EJ, Asztalos BF, et al. Characterization of high density lipoprotein particles in familial apolipoprotein A-I deficiency. J Lipid Res. 2008;49(2):349-57. (Pubitemid 351213619)
28. Tietjen I, Hovingh GK, Singaraja R, et al. Increased risk of coronary artery disease in Caucasians with extremely low HDL cholesterol due to mutations in ABCA1, APOA1, and LCAT. Biochim Biophys Acta. 2012;1821(3):416-24.
29. Haase CL, Frikke-Schmidt R, Nordestgaard BG, Tybjærg-Hansen A. Population-based resequencing of APOA1 in 10,330 individuals: spectrum of genetic variation, phenotype, and comparison with extreme phenotype approach. PLoS Genet. 2012;8(11):e1003063.
30. Haase CL, Frikke-Schmidt R, Nordestgaard BG, et al. Mutation in APOA1 predicts increased risk of ischaemic heart disease and total mortality without low HDL cholesterol levels. J Intern Med. 2011;270(2):136-46.
31. Strang AC, Hovingh GK, Stroes ESG, Kastelein JJP. The genetics of high-density lipoprotein metabolism: clinical relevance for therapeutic approaches. Am J Cardiol. 2009;104(10 Suppl):22E-31E.
32. Sirtori CR, Calabresi L, Franceschini G, et al. Cardiovascular status of carriers of the apolipoprotein A-IMilano mutant: the limone sul garda study. Circulation. 2001;103(15):1949-54. (Pubitemid 32322221)
33. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003;290(17):2292-300. (Pubitemid 37430562)
34. Favari E, Gomaraschi M, Zanotti I, et al. A unique protease-sensitive high density lipoprotein particle containing the apolipoprotein A-I(Milano) dimer effectively promotes ATP-binding Cassette A1-mediated cell cholesterol efflux. J Biol Chem. 2007;282(8):5125-32. (Pubitemid 47093758)
35. Ibanez B, Giannarelli C, Cimmino G, et al. Recombinant HDL(Milano) exerts greater anti-inflammatory and plaque stabilizing properties than HDL(wild-type). Atherosclerosis. 2012;220(1):72-7.
36. Alexander ET, Weibel GL, Joshi MR, et al. Macrophage reverse cholesterol transport in mice expressing ApoA-I Milano. Arterioscler Thromb Vasc Biol. 2009;29(10):1496-501.
37. Osei-Hwedieh DO, Amar M, Sviridov D, Remaley AT. Apolipoprotein mimetic peptides: Mechanisms of action as anti-atherogenic agents. Pharmacol Ther. 2011;130(1):83-91.
38. Bodzioch M, Orsó E, Klucken J, et al. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat Genet. 1999;22(4):347-51. (Pubitemid 29369524)
39. Brooks-Wilson A, Marcil M, Clee SM, et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet. 1999;22(4):336-45. (Pubitemid 29369523)
40. Rust S, Rosier M, Funke H, et al. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet. 1999;22(4):352-5. (Pubitemid 29369525)
41. Frikke-Schmidt R. Genetic variation in the ABCA1 gene, HDL cholesterol, and risk of ischemic heart disease in the general population. Atherosclerosis. 2010;208(2):305-16.
42. Candini C, Schimmel AW, Peter J, et al. Identification and characterization of novel loss of function mutations in ATP-binding cassette transporter A1 in patients with low plasma high-density lipoprotein cholesterol. Atherosclerosis. 2010;213(2):492-8.
43. Frikke-Schmidt R, Nordestgaard BG, Jensen GB, Tybjaerg-Hansen A. Genetic variation in ABC transporter A1 contributes to HDL cholesterol in the general population. J Clin Invest. 2004;114(9):1343-53. (Pubitemid 40385306)
44. Frikke-Schmidt R, Nordestgaard BG, Jensen GB, et al. Genetic variation in ABCA1 predicts ischemic heart disease in the general population. Arterioscler Thromb Vasc Biol. 2008;28(1):180-6.
45. Frikke-Schmidt R, Nordestgaard BG, Schnohr P, et al. Mutation in ABCA1 predicted risk of ischemic heart disease in the Copenhagen City Heart Study Population. J Am Coll Cardiol. 2005;46(8):1516-20. (Pubitemid 41446188)
46. Zwarts KY, Clee SM, Zwinderman AH, et al. ABCA1 regulatory variants influence coronary artery disease independent of effects on plasma lipid levels. Clin Genet. 2002;61(2):115-25. (Pubitemid 36372616)
47. Jensen MK, Pai JK, Mukamal KJ, et al. Common genetic variation in the ATP-binding cassette transporter A1, plasma lipids, and risk of coronary heart disease. Atherosclerosis. 2007;195(1):e172-80. (Pubitemid 47561955)
48. Villarreal-Molina T, Posadas-Romero C, Romero-Hidalgo S, et al. The ABCA1 Gene R230C variant is associated with decreased risk of premature coronary artery disease: The Genetics of Atherosclerotic Disease (GEA) Study. PLoS One. 2012;7(11):e49285.
49. Frikke-Schmidt R, Nordestgaard BG, Stene MCA, et al. Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA. 2008;299(21):2524-32. (Pubitemid 351787208)
50. Yvan-Charvet L, Wang N, Tall AR. Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses. Arterioscler Thromb Vasc Biol. 2010;30(2):139-43.
51. Sacco J, Adeli K. MicroRNAs: emerging roles in lipid and lipoprotein metabolism. Curr Opin Lipidol. 2012;23(3):220-5.
52. Calkin AC, Tontonoz P. Liver x receptor signaling pathways and atherosclerosis. Arterioscler Thromb Vasc Biol. 2010;30(8):1513-8.
53. Michael DR, Ashlin TG, Buckley ML, Ramji DP. Liver X receptors, atherosclerosis and inflammation. Curr Atheroscler Rep. 2012;14(3):284-93.
54. Zhang Y, Breevoort SR, Angdisen J, et al. Liver LXRα expression is crucial for whole body cholesterol homeostasis and reverse cholesterol transport in mice. J Clin Invest. 2012;122(5):1688-99.
55. Rayner KJ, Esau CC, Hussain FN, et al. Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature. 2011;478(7369):404-7.
56. Singaraja RR, Visscher H, James ER, et al. Specific mutations in ABCA1 have discrete effects on ABCA1 function and lipid phenotypes both in vivo and in vitro. Circ Res. 2006;99(4):389-97. (Pubitemid 44253695)
57. Rousset X, Shamburek R, Vaisman B, et al. Lecithin cholesterol acyltransferase: an anti- or pro-atherogenic factor? Curr Atheroscler Rep. 2011;13(3):249-56.
58. Kuivenhoven JA, Pritchard H, Hill J, et al. The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes. J Lipid Res. 1997;38(2):191-205. (Pubitemid 27118033)
59. Duivenvoorden R, De Groot E, Elsen BM, et al. In vivo quantification of carotid artery wall dimensions: 3.0-Tesla MRI versus B-mode ultrasound imaging. Circ Cardiovasc Imaging. 2009;2(3):235-42.
60. Duivenvoorden R, Holleboom AG, Van den Bogaard B, et al. Carriers of lecithin cholesterol acyltransferase gene mutations have accelerated atherogenesis as assessed by carotid 3.0-T magnetic resonance imaging [corrected]. J Am Coll Cardiol. 2011;58(24):2481-7.
61. Van den Bogaard B, Holleboom AG, Duivenvoorden R, et al. Patients with low HDL-cholesterol caused by mutations in LCAT have increased arterial stiffness. Atherosclerosis. 2012;225(2):481-5.
62. AlphacorePharma, Press release October 9 2012. Available from: www.alphacorepharm/in-the-news.
63. Albers JJ, Vuletic S, Cheung MC. Role of plasma phospholipid transfer protein in lipid and lipoprotein metabolism. Biochim Biophys Acta. 2012;1821(3):345-57.
64. Yazdanyar A, Yeang C, Jiang X-C. Role of phospholipid transfer protein in high-density lipoprotein- mediated reverse cholesterol transport. Curr Atheroscler Rep. 2011;13(3):242-8.
65. Cheung MC, Wolfbauer G, Deguchi H, et al. Human plasma phospholipid transfer protein specific activity is correlated with HDL size: implications for lipoprotein physiology. Biochim Biophys Acta. 2009;1791(3):206-11.
66. Vergeer M, Boekholdt SM, Sandhu MS, et al. Genetic variation at the phospholipid transfer protein locus affects its activity and high-density lipoprotein size and is a novel marker of cardiovascular disease susceptibility. Circulation. 2010;122(5):470-7.
67. Jarvik GP, Rajagopalan R, Rosenthal EA, et al. Genetic and nongenetic sources of variation in phospholipid transfer protein activity. J Lipid Res. 2010;51(5):983-90.
68. Moerland M, Samyn H, Van Gent T, et al. Acute elevation of plasma PLTP activity strongly increases pre-existing atherosclerosis. Arterioscler Thromb Vasc Biol. 2008;28(7):1277-82.
69. Luo Y, Shelly L, Sand T, et al. Pharmacologic inhibition of phospholipid transfer protein activity reduces apolipoprotein-B secretion from hepatocytes. J Pharmacol Exp Ther. 2010;332(3):1100-6.
70. Inazu A, Brown ML, Hesler CB, et al. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med. 1990;323(18):1234-8. (Pubitemid 20366528)
71. Barter PJ, Rye K-A. Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk. J Lipid Res. 2012;53(9):1755-66.
72. Zhong S, Sharp DS, Grove JS, et al. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest. 1996;97(12):2917-23. (Pubitemid 26197108)
73. Hirano K, Yamashita S, Nakajima N, et al. Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity. Arterioscler Thromb Vasc Biol. 1997;17(6):1053-9. (Pubitemid 27260323)
74. Johannsen TH, Frikke-Schmidt R, Schou J, et al. Genetic inhibition of CETP, ischemic vascular disease and mortality, and possible adverse effects. J Am Coll Cardiol. 2012;60(20):2041-8. This is an interesting study in the light of recent CETP inhibitor drug development. This study showed a significant association between genetic inhibition of CETP and CVD risk.
75. Boekholdt SM, Sacks FM, Jukema JW, et al. Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects. Circulation. 2005;111(3):278-87. (Pubitemid 40165333)
76. Thompson A, Di Angelantonio E, Sarwar N, et al. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA. 2008;299(23):2777-88. (Pubitemid 351846853)
77. Ridker PM, Paré G, Parker AN, et al. Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: Genomewide analysis among 18 245 initially healthy women from the Women's Genome Health Study. Circ Cardiovasc Genet. 2009;2(1):26-33.
78. Kathiresan S. Will cholesteryl ester transfer protein inhibition succeed primarily by lowering low-density lipoprotein cholesterol? Insights from human genetics and clinical trials. J Am Coll Cardiol. 2012;60(20):2049-52.
79. Vergeer M, Korporaal SJA, Franssen R, et al. Genetic variant of the scavenger receptor BI in humans. N Engl J Med. 2011;364(2):136-45. This was the first study to report SR-B1 variants in humans associated with HDL-C and reduced macrophage cholesterol efflux.
80. Brunham LR, Tietjen I, Bochem AE, et al. Novel mutations in scavenger receptor BI associated with high HDL cholesterol in humans. Clin Genet. 2011;79(6):575-81.
81. Chadwick AC, Sahoo D. Functional characterization of newly-discovered mutations in human SR-BI. PLoS One. 2012;7(9):e45660.
82. Singaraja RR, Sivapalaratnam S, Hovingh K, et al. The impact of partial and complete loss of function mutations in endothelial lipase on HDL levels and functionality in humans. Circ Cardiovasc Genet. 2012. doi: 10.1161/CIRCGENETICS. 111.962613.
83. Vergeer M, Cohn DM, Boekholdt SM, et al. Lack of association between common genetic variation in endothelial lipase (LIPG) and the risk for CAD and DVT. Atherosclerosis. 2010;211(2):558-64.
84. Edmondson AC, Brown RJ, Kathiresan S, et al. Loss-of-function variants in endothelial lipase are a cause of elevated HDL cholesterol in humans. J Clin Invest. 2009;119(4):1042-50.
85. Jensen MK, Rimm EB, Mukamal KJ, et al. The T111I variant in the endothelial lipase gene and risk of coronary heart disease in three independent populations. Eur Heart J. 2009;30(13):1584-9.
86. Willer CJ, Sanna S, Jackson AU, et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet. 2008;40(2):161-9. (Pubitemid 351171403)
87. Waterworth DM, Ricketts SL, Song K, et al. Genetic variants influencing circulating lipid levels and risk of coronary artery disease. Arterioscler Thromb Vasc Biol. 2010;30(11):2264-76.
88. Takeuchi F, Isono M, Katsuya T, et al. Association of genetic variants influencing lipid levels with coronary artery disease in Japanese individuals. PLoS One. 2012;7(9):e46385.
89. Chen X, Li S, Yang Y, et al. Genome-wide association study validation identifies novel loci for atherosclerotic cardiovascular disease. J Thromb Haemost. 2012;10(8):1508-14.
90. Small KS, Hedman AK, Grundberg E, et al. Identification of an imprinted master trans regulator at the KLF14 locus related to multiple metabolic phenotypes. Nat Genet. 2011;43(6):561-4.
91. Schunkert H, König IR, Kathiresan S, et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet. 2011;43(4):333-8.
92. •• Deloukas P, Kanoni S, Willenborg C, et al. Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet. 2012;45:25-33. This is the largest and most recent meta-analysis on the genetic background of coronary artery disease risk.
93. Van Eck M, Twisk J, Hoekstra M, et al. Differential effects of scavenger receptor BI deficiency on lipid metabolism in cells of the arterial wall and in the liver. J Biol Chem. 2003;278(26):23699-705. (Pubitemid 36830193)